Latest France News

Prescient Therapeutics has reached the first planned review threshold in its PTX-100 Phase 2a lymphoma study, while a completed A$6.0 million raise extends funding beyond the December milestone. The review will assess safety and efficacy, but is not a study completion or a new clinical result.

WCM Global Growth Limited (ASX:WQG) lifted its fully franked final dividend after posting a $66.7 million FY2026 profit and expanding its asset base by 31%. The portfolio lagged its benchmark for the year, but long-term returns remained ahead.

Medical Developments International returned to EBIT profitability in FY26 as Penthrox volumes strengthened across Australian hospitals and Europe. The company now faces the less glamorous test of converting regulatory progress into repeatable demand while absorbing weaker Respiratory sales and new amortisation costs.

Lotus Resources has executed key documentation for a Mercuria facility providing up to US$30 million in inventory-backed prepayment funding, while only one major approval remains before Kayelekera’s first uranium shipment. Operations are improving, but production remains tied to acid availability and power reliability.

Eden Innovations reported a sharp acceleration in US sales during Q1 FY27, led by a 247% jump in OptiBlend revenue and expanding EdenCrete plant installations. The figures are unaudited management results, but they give the company a stronger opening quarter for the new financial year.

Apollo Minerals ended 2026 with A$7.74 million in cash and no debt after raising A$9.3 million, but remains a loss-making explorer with no JORC Mineral Resources or production. The company is now concentrating its exploration story on the reinstated Couflens tungsten-gold project in France, while carrying a conceptual zinc-lead target in Gabon.

Atlas Arteria has warned that France may more than double the tax rate applied to eligible toll-road operators, with APRR’s 2025 TEILD bill already reaching €126.7 million. The proposed changes remain subject to parliamentary debate and could be softened before becoming law.

Cobalt Blue has cleared important technical and regulatory hurdles at its Kwinana refinery, but the pre-revenue developer says further funding is needed and auditors flagged material uncertainty over its ability to continue as a going concern. The company reported an A$8.797 million loss for FY2026 despite ending the year with A$4.265 million in cash.

Apollo Minerals has completed a 180-line-kilometre airborne magnetic and radiometric survey over its Couflens tungsten-gold project in France, with the work conducted alongside the French Geological Survey. The data is still being processed, but it could help shape the next phase of exploration, including planned underground drilling at the Véronique zone.

Vulcan Energy has started commercial-scale production in Germany of VULSORB, the proprietary adsorbent at the centre of its planned direct lithium extraction process. The material will supply first-fill volumes for Project Lionheart, although lithium production remains targeted for the second half of 2028.

Atlas Arteria will pay securityholders an unfranked distribution of 20.0 Australian cents per stapled security for the six months to 30 June 2026. Securities go ex-entitlement on 23 September, with payment estimated for 7 October.

Dyno Nobel has reaffirmed its FY26 outlook and retained its A$600 million FY28 underlying EBIT ambition, while setting a new A$800 million target for FY31. The explosives maker is positioning defence energetics, premium technology and growth in mining markets as the next leg of expansion.